Published

Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: AJOB empirical bioethics
Date: 2025-01-01
Source: PubMed
DOI: 10.1080/23294515.2025.2526339
PubMed: 40668936

Authors

Cheung K Propes C Graziosi M Patch K Yaden DB

Watch author

Derived topics and classifications

psilocybin Consciousness Clinical Trial Review Article Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study2026-08-01 Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis.2025-01-01

Related papers

Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included?Ask the expert - Psychedelic substances · 2024-08-31 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04 A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)ClinicalTrials.gov · 2024-08-15